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Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive
(HR) breast cancer cases even when HER2 is overexpressed. Evocative data suggest that HER2-positive
breast cancer patients are a heterogeneous population and a subset of HER2-positive and HR-positive
tumors biologically behave more like HER2-negative. Identiﬁcation and targeted monitoring of these
patients is crucial to consolidate data aiming to optimize combination treatment with new agents,
thereby avoiding overtreatment with chemotherapy. The questions surrounding HER2-positive and HR-
positive breast cancer patients treatment as well as the potential direction towards development of
surrogate markers alternative to pCR are discussed.
 2013 Elsevier Ltd. All rights reserved.Introduction
Neoadjuvant trials are a new and reliable approach to testing
new agents for breast cancer (BC). Aside from the clinical beneﬁt
derived by tumor downstaging, neoadjuvant therapy may provide
in fact valuable prognostic information, considering that patients
achieving pathologic complete response (pCR) show improved
long-term outcome as compared to those left with residual disease
after neoadjuvant systemic therapy. Based on this evidence, the
FDA recently released speciﬁc guidelines to use pCR as a surrogate
endpoint to support accelerated drug approval for BC neoadjuvant
treatment [1]. To date, however, there has not been a uniform
deﬁnition of pCR, which has made reporting and interpretation of
data fromneoadjuvant trials challenging. The FDA has proposed the
following deﬁnition for regulatory purposes: pCR is deﬁned as the
absence of any residual invasive cancer on hematoxylin and eosin
evaluation of the resected breast specimen and all sampled ipsi-
lateral lymph nodes following completion of neoadjuvant systemic
therapy. Adoption of a single termwith a standard deﬁnitionwould
facilitate discussion of proposed trial designs and interpretation ofFondazione IRCCS e Istituto
aly. Tel.: þ39 02 2390 30 66;
i.it (S. Di Cosimo).
All rights reserved.clinical trial data to support accelerated approval. Importantly, ac-
cording to FDA, the deﬁnition of pCR proposed in their guidance
would have the greatest likelihood of predicting clinical beneﬁt for
regulatory purposes in patients with early-stage breast cancer who
achieve pCR following neoadjuvant systemic therapy. However,
pCR rates signiﬁcantly vary depending on BC subtypes, ranging
from 8.3% in hormone receptor-positive (HR-positive) to 31.1% in
triple negative cases, with aggressive subtypes more highly asso-
ciated with event-free survival than smaller, less aggressive tumors
[2]. In patients with HER2 overexpressing (HER2-positive) BC,
trastuzumab dramatically changed the disease’s natural history and
improved outcome [3,4]. However, pCR rates of neoadjuvant
trastuzumab-containing regimes are still in the range of 30e60%
with 3-year relapse-free survival (RFS) of 71e78% [5], clearly
showing that a substantial number of HER2-positive BC patients
undergoing surgery still present residual disease notwithstanding
prior neoadjuvant therapy.Signiﬁcance of pCR in HER2-positive and HR-positive tumors
Growing evidence indicates that response to anti-HER2 agents
and the prognostic impact of pCR after anti-HER2-based therapy
depend on HR status. In the retrospective study by Guarneri et al.,
pCR rates among patients with HER2-positive BC treated with
anthracycline/taxane-based chemotherapy was 15% and 29%
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The addition of trastuzumab produced similar differences accord-
ing to HR status, with pCR rates 1.5e2 fold lower in HR-positive
than in -negative cases [6]. More recently, data from the Neo-
Sphere [7], NeoALTTO [8] and TBCRC006 [9] trials further
conﬁrmed these ﬁndings, consistently showing that pCR rates were
signiﬁcantly lower in HR-positive than HR-negative tumors,
regardless the type of HER2-targeted therapy with single or com-
bined HER2 blockade (Table 1) [7e19]. Therefore, new neoadjuvant
strategies are urgently needed to increase pCR rates and to improve
clinical outcome of HER2-positive/HR-positive BC patients.
Nevertheless, the signiﬁcance of pCR in this subset of patients
needs further considerations. The pooled analysis of the German
neoadjuvant studies reported that pCR is a suitable surrogate
endpoint for HER2-positive/HR-negative but not for HER2-positive/
HR-positive BC patients [20]. Indeed, pCR in HER2-positive/HR-
positive cases was relatively uncommon (11%e22%), even with the
use of trastuzumab, and achievement of pCR in this subgroup was
not prognostic for survival. Although the reasons for these ﬁndings
are not entirely clear, a possible explanation is that lack of pCR to
chemotherapy in less proliferative HR-positive tumors predicts
greater beneﬁt to future hormonotherapy. Thus patients with
HER2-positive/HR-positive BC not achieving a pCR are not neces-
sarily at poor prognosis, as adjuvant hormonotherapy may further
improve clinical outcome. It is important to note, however, that
among patients with pCR, those initially diagnosed with HER2-
positive/HR-positive BC tend to report the lowest 5-year disease-
free survival (DFS) as if, when present, pCR in HER2-positive/HR-
positive cases is less beneﬁcial. Although no analysis on biologicalTable 1
Pathological complete response (pCR)a rate according to hormone-receptor (HR) status i
Study [Ref] phase No. of
patients
Clinical
stage
Neoadjuvant
Randomized trials
with trastuzumab
MD Anderson [10]
Phase III
42 IIeIII P/ FEC
P þ T/ FEC
NOAH [11]
Phase III
235 III AP/ P/ C
AP þ T/ P
ABCSG-24 [12]
Phase III
90 IIeIII EC  Cap
EC  Cap þ
REMAGUS 02 [13]
Phase II
120 IIeIII EC/ D
EC/ D þ T
H2269s [14]
Phase II
30 IIeIII D þ CBDCA
D þ CBDCA
Randomized trials
comparing
HER2-targeting
approaches
NeoALTTO [8]
Phase III
455 IIeIII Weekly P þ
Weekly P þ
Weekly P þ
NeoSphere [7]
Phase III
417 IIeIII D þ T
D þ Pert
D þ Pert þ T
Pert þ T
NSABP B-41 [15]
Phase III
519 IIeIII AC/ weekl
AC/ weekl
AC/ weekl
GeparQuinto [16]
Phase III
615 IIeIII EC þ T/ D
EC þ L/ D
CHERLOB [17]
Phase II
121 IIeIII P þ T/ FEC
P þ L/ FEC
P þ T þ L/
GEICAM 2006e14 [18]
Phase II
99 IIeIII EC/ D þ T
EC/ D þ L
Holmes et al. [19]
Phase II
100 IIeIII FEC/ week
FEC/ week
FEC/ week
A ¼ doxorubicin; Cap ¼ capecitabine; CBDCA ¼ carboplatin; CMF ¼ cyclophosphamide,
epirubicin, and cyclophosphamide; L ¼ lapatinib; NR ¼ not reported; P ¼ paclitaxel; Per
a pCR ¼ deﬁned as no invasive tumor in the breast and axilla, if not otherwise speciﬁ
b Comparison between dual HER2-targeted therapy þ chemotherapy versus trastuzumand clinical characteristics of these patients relapsing after pCR has
been done, it is likely that the poorer outcome in this subgroup is
due to either decreased beneﬁt from adjuvant therapy or rapid
onset of molecular resistance to anti-HER2 agents and/or hormo-
notherapy. In support of this hypothesis, evidence exists that re-
lapses after pCR generally occur in young patients and/or in
patients with locally advanced BC at presentation [21]. Therefore, in
patients with HER2-positive/HR-positive, pCR is infrequent and
when reported it does not yield the same good outcome as
compared to the rest of patients treated with trastuzumab-based
neoadjuvant regimens. Data from adjuvant studies further
conﬁrm these ﬁndings [22]. In the HERA trial, the hazard ratio for
DFS among patients with HER2-positive/HR-positive early BC had
the widest conﬁdence intervals as compared with the other sub-
types. Although the limitations of the post-hoc analysis permit no
deﬁnitive conclusion on the differential effect of adjuvant trastu-
zumab according to BC subtypes, these data demonstrate that
HER2-positive BC patients are a heterogeneous population. The
identiﬁcation and characterization of the HER2-positive/HR-posi-
tive BC subset is essential to avoid overtreatment especially in pa-
tients with small tumors, who may beneﬁt from hormonotherapy
alone or combined with a HER2 targeted therapy without chemo-
therapy. Indeed, a crosstalk between the HR and HER2 pathways
exists, which plays amajor role in the development of both intrinsic
and acquired resistance to endocrine agents. Emerging data sug-
gests that this crosstalk is bidirectional and is involved in resistance
to HER2-directed agents [23]. Therefore, targeting both HR and
HER2 pathways may be beneﬁcial in overcoming resistance to
endocrine and anti-HER therapies and optimize clinical outcome.n neoadjuvant trials with anti-HER2 agents.
regimen pCR rate p pCR rate
HR-positive
pCR rate
HR-negative
þ T
26%
65%
0.016 27.2%
61.5%
25%
70%
MF
þ T/ CMF þ T
19%
38%
0.001 17%
18%
22%
48%
T
26% (breast only)
40% (breast only)
0.369 NR NR
19%
26%
NR 20.5%
20.5%
19%
32%
þ T
7.1% (breast only)
40% (breast only)
0.0801 NR NR
T
L
T þ L
28%
20%
47%
0.0007b 22.7%
16.1%
41.6%
36.5%
33.7%
61.3%
23%
17%
42%
12%
0.0141b 20%
17.4%
26%
5.9%
36.8%
30%
63.2%
27.3%
y P þ T
y P þ L
y P þ T þ L
49.4%
47.4%
60.2%
0.056b 46.7%
48%
55.6%
65.5%
60.6%
73%
þ T
þ L
44%
30%
0.04 NR NR
þ T
þ L
FEC þ T þ L
25%
26.3%
46.7%
0.019b 25%
22.7%
35.7%
26.6%
35.7%
56.2%
48%
24%
0.01 NR NR
ly P þ T
ly P þ L
ly P þ T þ L
54%
45%
74%
NR NR NR
methotrexate, 5-ﬂuorouracil; D ¼ docetaxel; E ¼ epirubicin; FEC ¼ 5-ﬂuorouracil,
t ¼ pertuzumab; T ¼ trastuzumab.
ed.
ab þ chemotherapy.
Table 2
Summary of studies assessing biomarkers in HER2 positive breast cancer.
Biological markers Type of study [Ref] Patient
population
(n)
Results Conclusion/remarks
Proteins Basal p95/HER2 Retrospective [37] MBC (93) Decreased PFS (HR 1.9; p ¼ 0.017)
and OS (HR 2.2; p ¼ 0.012) as
compared with p95/HER2 negative
p95/HER2 is a marker of
poor prognosis (TBC in RCT)
Analysis from RCT
[38,17]
NeoAdj (153) pCR 58.2% vs 32.6% in
p95/HER2-negative vs
positive pts (0.009) in
the GeparQuattro study
No difference in the
CHERLOB study
Inconclusive data on p95/
HER2 predictive valueNeoAdj (88)
Basal Ki67 Analysis from RCT [39] NeoAdj (1166) Ki67 signiﬁcantly linked
to prognosis in uni- and
multivariate analysis
Ki67 is associated with poor
prognosis and increased pCR
(TBC in RCT)
Ki67  15% vs 15.1%e35%
vs > 35% had pCR% of 4.2%,
12.8%, and 29.0% (p < 0.0005)
Post-therapy
Ki67
Retrospective [28,40] NeoAdj (102) High Ki67 expression correlated
with poor DFS and OS
Prognostic value of post
treatment Ki67 to be further
investigatedNeoAdj (64) Multivariate analysis showed
Ki67 signiﬁcantly (p ¼ 0.05)
associated with prognosis
Basal and
post-therapy
TOPOIIa
Retrospective [41] NeoAdj (283) Decreased DFS (p ¼ 0.010)
and OS (p < 0.001) in TOPOIIa
cases Signiﬁcant prognostic
value of post-treatment TOPOIIa
(p ¼ 0.002)
Prognostic value of TOPOIIa to
be further investigated
Loss of PTEN
and p110
expression
Retrospective [42] MBC, EBC (155) Decreased PFS correlated with
basal expression of p110a
(p ¼ 0.024)
Prognostic value of PI3K activation
to be further investigated
Immunological-
related
FcYR Retrospective [34] MBC, EBC (54) 158 V/V genotype correlated
with ORR (HR, 8.7; p ¼ 0 0.02)
and PFS (HR 5.3; p ¼ 0.005)
FcYR-mediated ADCC to be
further investigated
Lymphocyte
Inﬁltration
Retrospective [32]
Retrospective [43]
NeoAdj [25]
EBC (1250)
Higher inﬁltration of CD8þ T cells,
FOXP3(þ) regulatory T cells (Tregs)
and CD8(þ) cytotoxic T lymphocytes
as compared to HER2 negative cases
(p < 0.005)
Value of reduced tumor-related
immune suppression to be further
investigated
Geneproﬁle Blueprint
PAM50
Retrospective [31]
Retrospective [30]
NeoAdj (996)
NeoAdj (437)
Increased predictive accuracy for pCR
by adding the immune module to
clinicopathologic characteristics
(IDI, 0.093; p ¼ 0.004) 40% of
HER2-positive cases are luminal-type
by BluePrint and
present low response rates to therapy
Immune module scores and
molecular subtyping improve
estimation of pCR
(to be further investigated)
Prospective [44] MBC [19] High expression of 17q12-21 amplicon
genes HER2 and GRB7 correlated with
response to treatment (p ¼ 0.0015)
PAM50-enriched proﬁle associated
with clinical beneﬁt
(to be further investigated)
Functional
pathway
PI3KCA Retrospective [36] NeoAdj [46] Alterations of PI3K genes are more
frequent in HER2 positive cases
without HER2 ampliﬁcation (p ¼ 0.009)
PTEN loss and PIK3CA mutations
confer worse outcome and
resistance to trastuzumab
(TBC in RCT)Retrospective [45]
Rettrospective [46]
NeoAdj, EBC,
MBC (1889)
NeoAdj (80)
PTEN loss correlated with poorer
efﬁcacy of trastuzumab (RR ¼ 0.682, 95%
CI: 0.550e0.846, p ¼ 0.000) PIK3CA
mutations correlated to
decreased DFS (p ¼ 0.0013)
Metabolic proﬁle 18FDG PET Analysis from RCT [47] NeoAdj (86) pCR rates twice as high for18FDG PET
responders than non-responders
(44% vs 19%, p ¼ 0.05)
Metabolic responders have
increased likelihood of pCR
(to be further investigated)
Soluble Circulating
Tumor Cells
Prospective [48] EBC (88) CTCs are related to reduced DFS
(p < 0.023) and OS (p < 0.04)
CTCs predict poor clinical
outcome (to be further
investigated)Retrospective [49] MBC (53) CTC count is a signiﬁcant predictive
factor for OS (p < 0.01)
Circulating
Endothelial Cells
Retrospective [50] NeoAdj (53) Low baseline CEC associated with pCR
(p ¼ 0.046)
Value of CEC to be assessed
in extensive studies
Retrospective [51] MBC [52] Clinical responses correlated with low CEC
(p ¼ 0.023)
HER2 Review [52] MBC, EBC No clear correlation with response to
treatment or OS
Prospective trials to investigate
the clinical use of HER2 ECD
test are needed
DFS¼ Disease Free Survival; EBC¼ early breast cancer; ECD ¼ extracellular domain; 18FDG PET ¼ 18-Fluoro-deoxyglucose positron emission tomography; HR¼ hazard ratio;
Integrated discrimination index (IDI); MBC ¼ metastatic breast cancer; NeoAdj ¼ neoadjuvant; ORR ¼ overall response rate; OS ¼ Overall Survival; pCR ¼ pathological
complete response, deﬁned as no invasive tumor in the breast and axilla, if not otherwise speciﬁed; PFS ¼ Progression free survival; RCT ¼ randomized controlled trial;
RR ¼ relative risk; TBC ¼ to be conﬁrmed; vs ¼ versus.
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clinical outcome from neoadjuvant therapies
Understanding which patients are eligible for new treatments is
critical, especially in the neoadjuvant setting, where the lack of
prognostic value of pCR makes the identiﬁcation of alternative
markers a priority for cancer research. The proliferation index Ki67
is a feasiblemarkerwidely studied as surrogate of disease relapse in
patients undergoing neoadjuvant hormonotherapy. Results from a
randomized trial comparing tamoxifen versus anastrozole, showed
that differences in Ki67 suppression after 2 and 12 weeks of treat-
ment mirrored those in RFS in companion adjuvant trials [24].
Further evidence for the importance of Ki67 suppression were
provided by higher 2-week values of Ki67 predicting a signiﬁcantly
worse RFS [25]. However as HER2 positive tumors show poor
reduction in Ki67 upon treatment with aromatase inhibitors, this
marker may be of limited utility when used in the setting of neo-
adjuvant hormonotherapy [26]. Nevertheless, in BC patients
receiving neoadjuvant chemotherapy, basal Ki67 values predict
treatment response and prognosis, as the higher the basal Ki67 the
higher the pCR rate and RFS [27]; and, even more importantly, Ki67
values after treatment predict prognosis in patients not achieving a
pCR [28]. The use of Ki67 as a guide for neoadjuvant treatment has
been the focus of the Z1031B study [29]. All patients enrolled in this
study were initially treated with hormonotherapy during 2e4
weeks. A tumor biopsy was performed thereafter and, according to
the Ki67 results, patients who had tumors with a high proliferation
rate were recommended to switch to chemotherapy/surgery. The
study reported a pCR rate of 6% among those patients who switched
to neoadjuvant chemotherapy, which did not meet the study’s
predeﬁned criteria for adequate activity. Nevertheless, the value of
Ki67 inHER2-positve/HR-positive BC continues to be investigated in
different trials with anti-HER2 targeted agents  hormonotherapy,
i.e. NeoPhoebe, PAMELA, PERELISA,with the ultimate goal ofﬁnding
a valid strategy for patients unlikely to beneﬁt from chemotherapy.
In addition, clinical trials have already started to evaluate the utility
of using molecular proﬁles for breast cancer management in the
preoperative setting. Among these, the I -SPY I study tested the
MammaPrint and the BluePrint 80-gene expression proﬁles to
stratify response to neoadjuvant therapy according to molecular
subtypes. In detail, the pCR rate was 5% in the luminal-A and 10% in
luminal-B, 39% in HER2-type and 33% in the basal-like subtypes.
These data support the use of Mammaprint and BluePrint to deﬁne
the clinical correlation betweenmolecular subtyping and treatment
outcomes [30]. Furthermore, the pooled analysis, focusing on the
associations betweenpCR and genemodules todiscover biologically
relevant and potentially druggable subtype-speciﬁc oncogenic
pathways, showed a strong link between immunemodules and pCR
in HER2-positive tumors [31]. Both HER2 and estrogens have
immunomodulatory effects on BC development by increasing
intratumoral TRegs levels [32] and immunomodulation is a critical
factor for trastuzumab antitumoral activity. Several studies have
shown that in BC patients treated with trastuzumab-based therapy
[33] the antibody-dependent cell-mediated cytotoxicity (ADCC) and
the FcgR polymorphisms can reliably predict clinical response [34].
Enhancing antitumor immunity may therefore increase therapy
efﬁcacy in HER2-positive/HR-positive BC, a strategy that deserve
further investigations in clinical trials. Finally, sequencing analysis
in BC reported that dysregulation of the PI3K pathway is associated
with poor response to HER2-targeted therapy [35]. Furthermore,
alterations in the PI3K and HR signaling are prognostic for patient
outcome in the HR-positive BC subset [36]. The crosstalk between
PI3K and HR pathways is involved in resistance to chemotherapy
with trastuzumab, thus leading to the conclusion that HR status
inﬂuenced the prognostic signiﬁcance of genomic alterations inHER2-positive tumors. If these data will be further conﬁrmed, mu-
tation analysis of PI3K status should become part of the routine
biomarkers panel as it may be helpful in selecting the proper
treatment of patients with HER2-positive/HR-positive tumors.
Studies assessing biomarkers in HER2 positive breast cancer are
summarized in Table 2 [17,28,30e32,34,36e52].
Conclusions
The addition of trastuzumab to neoadjuvant chemotherapy
regimen signiﬁcantly increases the pCR rates in all HER2-positive
tumors. However, the beneﬁt of trastuzumab is highest in HR-
negative tumors and progressively decreases with increase in tu-
mor HR expression. This information prompts the search of new
strategies and/or new combination of therapies associated to an
increased pCR but also novel surrogate markers of long-term
outcome. Studies using surrogate markers as Ki67 and gene
ampliﬁcation and/or mutation are currently ongoing and promise
to assist not only the choice of best neoadjuvant therapeutical
approach but also to address the clinician in scheduling the proper
treatment in the adjuvant setting in the next future.
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